A team from Cuba’s Labiofam Entrepreneurial Group, the Cuban Government’s arm of medical and biological research in Cuba, will be visiting St. Lucia from the 7th to the 9th March 2012, to introduce the cancer fighting drug Vidatox 30CH made from the venom of a scorpion indigenous to Cuba. Research on this drug has been ongoing for the past 15 years, and it is now available in Central & South America, Europe, Asia and Cuba. The team is on a Caribbean tour which includes St. Lucia to promote the drug in the region.
The visiting team of physician Mariela Margarita Guevara Garcia, Head of Clinical Analysis Department and Inarvis Martinez Montes de Oca, Export Specialist for North America and the Caribbean at Labiofam, are following up on an earlier visit by a team of three in October 2011 who met with the Permanent Secretaries of Health and Agriculture, the Medical Association, the OECS Pharmaceutical Procurement Agency, The Chamber of Commerce and the mass media.
This visit which comes quickly on the heels of last year’s iniative, should pave the way for Vidatox 30CH to become available over the counter to patients looking for relief and cure from cancer diseases.
The following is some information about the drug:
Cancer diseases are one of the main causes of death today. For this reason, the International Scientific Community has been working tirelessly in its quest to find an effective cure that could slash the death rate these ailments generate. In this regard, the Labiofam Entreprenurial Group, the Medical & Biological research arm of the Cuban government, has been conducting studies for 15 years on a natural compound that could assist in this quest; the venom of the Rhopalurus Junceus, a scorpion indigenous to Cuba. In May 2011, Labiofam was finally able to register Vidatox 30 CH with the Cuban Authorities, as a cancer fighting drug that prolonged the life of cancer patients by boosting the immune system, reducing pain, and destroying cancerous tumours in some cases.
At first, the research was based on observations that this venom had been used by native Cubans for more than 200 years as medication for many ailments. However hands-on scientific experiments made headway in the bid to shed scientific light on the pharmaceutical potential of this venom. Experts from Labiofam were able to confirm the analgesic, anti-inflammatory and anti-tumorial properties of the venom which is the main ingredient of Vidatox 30 CH.
During the First International Congress Labiofam 2010, the latest results of the research were presented, including studies of the venom’s influence on a wide array of tumoral cells. In each case, the significant and differentiated toxicity of the Scorpion’s venom on epithelial-origin tumours, was clearly revealed.
As part of the scientific evidence, congress attendees watched footage of the venom, destroying tumoral cells. Studies allowed for the isolation of five peptides armed with the ability to inhibit the growth of tumoral cells and induce cell death through an apoptosis mechanism. This inhibiting action confirms the certainty of using this substance as a complementary treatment for tumoral diseases.
The most important development however, was that over 10,000 patients, 3500 of whom came from outside Cuba, diagnosed with different cancer diseases, and for whom conventional treatments had failed, have been assisted by the staff at the LABIOFAM Entrepreneurial Group. Patients suffering from tumors in the pancreas, bone marrow, prostate, lungs and other organs have dramatically improved their quality of life thanks to the use of Vidatox 30CH, the scorpion venom product with no known side effects.
Today, the Cuban Research Centre is working on the implementation of large-scale outputs of homeopathic drops that could allow for enhancing the application of this therapeutic method. Already Vidatox is being used in South & Central America, Europe, Asia, Cuba, and the Caribbean region is the obvious new market. However, knocking down the barriers of incredulity that stand in the way of traditional medicine as opposed to conventional treatments, is a challenge on the road ahead. In this effort, perseverance and scientific validation and more importantly good results , will be the best allies to success for Vidatox 30 CH as a cancer fighting drug in St. Lucia, and the wider region.